## Gastroenterology Infusion Order Form

# 🕐 AristaCare

### Phone: 888.860.8806 Fax: 315.728.2650

Patient Information	Prescriber & Shipping Information		
Patient Name: DOB:	Prescriber Name:		
Sex: O Female O Male SSN:	NPI:		
Language:Wt:O kg O lbs Ht:O cm O in	Address:		
Address:	Apt/Suite: City:State: Zip:		
Apt/Suite: City:State: Zip:	Contact:		
Phone:Alternate Phone:	Phone:Alternate Phone:		
Caregiver Name: Relation:	Fax:		
Local Pharmacy: Phone:	Email: O Ship to Physician's Office O Ship to Patient's Home		

#### Please fax a front and back copy of the Patient's Insurance Card(s)

#### Clinical Information (Please fax all pertinent clinical and lab information)

Diagnosis: O K50.90 Crohn's Disease O K51.90 Ulcerative Colitis	O Other:
Has patient received PPD (skin test)? O Yes O No Results:	
Prior Therapy O No O Yes List:	Reason for Discontinuation:
Approximate Start Date:	Approximate Stop Date:
Comorbidities:	
Concomitant Medications:	
Allergies O NKDA O Other :	Is this a first dose? Y N If not, date of last infusion:

Drug	How Supplied	Directions	Quantity	Refill
Entyvio® O 300mg vial		O Loading dose: Infuse 300mg IV over 30 minutes at week 0, week 2, and week 6	O 3 doses	
	O Maintenance dose: Infuse 300mg IV over 30 minutes every 8 weeks	O doses		
	O Other: Infuse 300mg IV over 30 minutes every weeks	- O doses		
Infliximab O 100mg vial O Dispense vials necessary to achieve dose	O 100mg vial	O Loading dose: Infusemg/kg IV over 2 hours at week 0, week 2, and week 6	O 3 doses	
	O Dispense vials	O Maintenance dose: Infusemg/kg IV over 2 hours every weeks		
	Patient Weight:kg	Odoses		
Skyrizi® (Induction dose) ○ 600mg/10ml vial	O Crohn's Loading Dose: Infuse 600mg IV over 1 hour at week 0, week 4, and week 8	O 3 vials		
	O Ulcerative Colitis Loading Dose: Infuse 1200mg IV over 2 hours at week 0, week 4, and week 8	O 6 vials	-	
Skyrizi® SubQ O 180mg/1.2ml O 360mg/2.4ml	O Maintenance dose: 180mg SubQ every 8 weeks starting at week 12 after the initial IV induction dose	- O 1 dose		
	O 360mg/2.4ml	O Maintenance dose: 360mg SubQ every 8 weeks starting at week 12 after the initial IV induction dose		
Stelara® (Induction dose) O 130mg/26ml vial	O Low-Dose induction: Infuse 130mg IV over at least 1 hour	O 1 vial		
	0 120mg/26ml vial	$O \le 55$ kg: Infuse 260mg IV over at least 1 hour	O 2 vials	
		O > 55kg to 85kg: Infuse 390 mg IV over at least 1 hour	O 3 vials	
		O >85kg: Infuse 520mg IV over at least 1 hour	O 4 vials	
Stelara <sup>®</sup> SubQ	O 1 x 90mg/ml PFS	O Inject 90mg SubQ 8 weeks after initial IV dose and then every 8 weeks thereafter	O 1 syringe	
Tysabri®	O 300mg/15ml vial	O Infuse 300mg IV over 1 hour every 4 weeks	O 1 vial	
TPN (Total Parent	eral Nutrition) in the home	setting: Please send orders separately.		
Other Miscellaneous Orders:		0		
Other Miscellaneous Orders:		0		
Injection Training	g Provided by: O Physic	ian's Office O Pharmacy O Other:		
Per state-specifi	c law, prescriptions may	be dispensed as generic, if applicable, unless marked "dispense as written"		
Prescriber's Sig	nature	Date:		

I authorize the Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at anytime by providing written notice to the pharmacy. Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from dissemination or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling (888) 860-8806 to obtain instructions as to proper destruction of the transmitted material. Thank you.